Natco Pharma's Q3 consolidated net profit dips 22% yoy at Rs 62 cr

Natco Pharma on Thursday said its consolidated net profit declined by 22 per cent to Rs 62 crore for the third quarter ended December 31, 2022

Medicines, Pharma
Press Trust of India New Delhi
1 min read Last Updated : Feb 09 2023 | 6:19 PM IST

Natco Pharma on Thursday said its consolidated net profit declined by 22 per cent to Rs 62 crore for the third quarter ended December 31, 2022.

The Hyderabad-based drug firm had reported a net profit of Rs 80 crore in the October-December quarter of last fiscal.

Total income of the company stood at Rs 513 crore in the period under review as compared with Rs 591 crore in the year-ago period that had a one-time licensing revenue.

The company's board, which met on Thursday, approved an interim dividend of Rs 1.25 per share for the quarter ended December 31, 2022.

Shares of the company ended 0.38 per cent down at Rs 529.10 apiece on the BSE.

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

Subscribe to Business Standard digital and get complimentary access to The New York Times

Quarterly Starter

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

Save 46%

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Access to Exclusive Premium Stories Online

  • Over 30 behind the paywall stories daily, handpicked by our editors for subscribers

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

Topics :Nacto PharmaQ3 resultspharmaceutical firms

First Published: Feb 09 2023 | 6:19 PM IST

Next Story